Citigroup - Mylan "buy"

http://www.ariva.de/news/...ncrease-in-First-Quarter-2013-Adj-4518092 GrB  

Specialty L.P. Calls on Communities Nationwide to Join The Food Allergy Research & Education (FARE) Walk for Food Allergy17:15 10.05.13


PR Newswire

BASKING RIDGE, N.J., May 10, 2013

BASKING RIDGE, N.J., May 10, 2013 /PRNewswire/ -- In recognition of Food Allergy Awareness Week, Mylan Specialty L.P., the fully integrated specialty pharmaceutical business of Mylan Inc. (NASDAQ: MYL), today announced their participation as the national presenting sponsor of the Food Allergy Research & Education (FARE) Walk for Food Allergy. With an estimated one in 13 children in the U.S. living with a food allergy, a considerable increase from previously reported figures, the walks bring together communities across the country to raise funds for important food allergy research, education, advocacy and awareness.

"Mylan Specialty is honored to support the FARE Walk for Food Allergy for the seventh consecutive year," said Heather Bresch, CEO of Mylan Inc. "We remain committed to those with potentially life-threatening or severe allergies, and given the growing incidence of food allergies, it's important that we continue to raise awareness to ensure that everyone is prepared to manage a life-threatening allergic reaction. The FARE Walk for Food Allergy aims to accomplish just that, by joining people together in a way that inspires others, motivates change and drives conversation about this significant public health issue."

Food allergies are a common cause of anaphylaxis, a life-threatening allergic reaction. The most common food allergens include peanuts, tree nuts, shellfish, fish, dairy, soy, eggs and wheat. People with severe allergies should have an anaphylaxis action plan in place, which includes avoiding known allergens, recognizing symptoms, having access to two epinephrine auto-injectors at all times and seeking immediate emergency medical care should anaphylaxis occur.

"The FARE Walk for Food Allergy is one of our flagship programs, and we are pleased to again have Mylan Specialty on board as our presenting sponsor," said John L. Lehr, Chief Executive Officer of FARE. "This year, with more than 65 walks planned nationwide, the Walk program continues to raise critical funds for food allergy education programs, advocacy initiatives and research, and to bring together thousands of Americans to increase awareness and understanding of the life-altering and potentially life-threatening nature of food allergies."

For more information or to register for the FARE Walk for Food Allergy, visit www.foodallergywalk.org.

About Anaphylaxis

Anaphylaxis is a life-threatening allergic reaction that has many possible triggers, occurs quickly, without warning, and must be treated immediately with epinephrine. Symptoms may include hives or redness of the skin, tightness in the throat, nausea, dizziness, breathing problems, a decrease in blood pressure and/or fainting. Anaphylaxis can be caused by triggers such as food, stinging and biting insects, medicines, latex or even exercise. Epinephrine is the only first-line treatment for anaphylaxis. According to the food allergy guidelines developed by the National Institute of Allergy and Infectious Diseases, if experiencing anaphylaxis, a person should use an epinephrine auto-injector and seek immediate emergency medical attention. Epinephrine is a naturally-occurring hormone, also known as adrenaline, and it should be available at all times to patients at risk. Delays in epinephrine administration have been associated with negative health consequences, even possibly death.

About Mylan Specialty

Mylan Specialty, a subsidiary of Mylan Inc. (NASDAQ: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, life-threatening allergic reactions and psychiatric disorders. For more information, please visit www.mylanspecialty.com.

About Mylan

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

© 2013 Mylan Specialty L.P. All rights reserved.

NON-2013-0012

SOURCE Mylan Specialty L.P.


Quelle: PR Newswire  

Datum Erster Hoch Tief Schluss     Stücke Volumen
13.05.13 29,56 29,63 29,05  29,20 $ 3.630.897 106 M
GrB  

Tickertafel Anzeige::: 29,40 $ +0,68% +0,20 $  

die kalte Schulter11:29 15.05.13

PARSIPPANY (dpa-AFX) - Der Generikahersteller Actavis hat nach Informationen aus Kreisen ein Übernahmeangebot seines US-Konkurrenten Mylan (Mylan Aktie) ausgeschlagen. Mylan habe für den größeren Konkurrenten in der vergangenen Woche 15,3 Milliarden Dollar (rund 11,8 Mrd Euro) geboten, berichtet die Nachrichtenagentur Bloomberg in der Nacht zum Mittwoch unter Berufung auf mit der Transaktion vertraute Kreise.

Mylan ist vor dem deutschen Generikakonzern Stada (STADA Aktie) nach Umsatz die weltweite Nummer vier der Branche. Der US-Konzern habe seine Offerte abgegeben, nachdem Actavis Verhandlungen über eine Fusion mit dem kanadischen Pharmakonzern Valeant auf Eis gelegt hatte. Valeant soll nach Presseberichten mehr als 13 Milliarden Dollar geboten haben.

Actavis spricht derzeit mit dem irischen Konkurrenten Warner Chilcott über eine Übernahme. Die Verhandlungen seien in einem frühen Stadium und es gebe noch keine Übereinkunft, hatten beide Konzerne am Wochenende in Dublin und Parsippany mitgeteilt. Warner Chilcott hatte sich vor mehr als einem Jahr zum Verkauf gestellt.

In Deutschland wurde Actavis 2010 in Zusammenhang mit dem Übernahmekampf um den Ulmer Konkurrenten Ratiopharm bekannt. Nach monatelangem Ringen entschied letztendlich der Branchenriese Teva den Bieterkampf um Ratiopharm für sich und Actavis ging leer aus./ep/jha/fbr

Quelle: dpa-AFX  

Mylan Launches Generic Zomig® Tablets17:45 15.05.13


PR Newswire

PITTSBURGH, May 15, 2013

PITTSBURGH, May 15, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Zolmitriptan Tablets, 2.5 mg and 5 mg. This product is the generic version of IPR Pharmaceuticals Inc.'s Zomig® Tablets and is indicated for the acute treatment of migraine with or without aura in adults. Zolmitriptan Tablets are for use only where a clear diagnosis of migraine has been established.  If a patient does not respond after the first dose, a healthcare provider should reconsider the diagnosis before re-administering. The product is not indicated for the prevention of migraine attacks or cluster headaches.

Zolmitriptan Tablets, 2.5 mg and 5 mg, had U.S. sales of approximately $152.8 million for the 12 months ending March 31, 2013, according to IMS Health. Mylan has begun shipping this product.

Currently, Mylan has 178 ANDAs pending FDA approval representing $83.1 billion in annual sales, according to IMS Health.  Thirty-four of these pending ANDAs are potential first-to-file opportunities, representing $22.4 billion in annual brand sales, for the 12 months ending June 30, 2012, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.


Quelle: PR Newswire  

bereits bedient wurde:

Zeit  Kurs  Stück  
08:03:10 23,877 €  40

GrB  

31,40 $ 0,00% +0,00 $ , 17.05.13 , GrB  

Zeit  Kurs  Stück  
10:50:20 24,565 €  100  
10:22:28 24,58 €  80  
08:00:03 24,628 €  200
___________________

zweimal abgeordert ..einmal genommen ..GLÜCKWUNSCH  

RTK 31,29  $  ..3.288.748 Stücke gestemmt und bedient ..ask 31,30

.....alle Angeaben realtime und mit Russicher Kalaschnikoff ..buran  

http://www.ariva.de/news/...-Rules-in-Favor-of-Mylan-in-Paten-4536263 GrB  

http://www.ariva.de/news/...r-Julie-Bowen-Calls-on-Communitie-4536562 GrB  

RTK 31,96  $  somit +2,34% über EK ..dicke 1.341.017 Stücke unter die Wand gefeuert und bereits alle bedient ..max Leuchte 32,09

..hier nochmal >>> Dow 15.482 JOLLYPUNKTE und weitermachen und Dreimal Rosamunde und sowieso und überhaupt

buran,Der Mylander  

Buch dazu

Zeit  Kurs  Stück  
08:01:52 24,26 €  40

GRATULATION  

http://www.ariva.de/news/...-Announces-Partnership-with-Baseb-4544367 GrB  

.......ask 30,94 ..alles RT  

Amisatz 03-06

Datum Erster Hoch Tief Schluss     Stücke Volumen
03.06.13 30,46 30,85 30,11  30,40 $ 4.496.311 134 M

..........ask 30,89 aktuell  

Tickersatz dazu 05-06

Datum Erster Hoch Tief Schluss     Stücke Volumen
05.06.13 29,90 30,45 29,73  29,89 $ 5.405.028 138 M

GrB  

Mylan Laboratories, Ctrip Com, ResMed, and AOL Released By InvestorsObserver15:35 07.06.13


PR Newswire

CHICAGO, June 7, 2013

CHICAGO, June 7, 2013 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PCLN, MYL, CTRP, RMD, and AOL.

(Logo: http://photos.prnewswire.com/prnh/20120712/CG39046)

To see what our analysts have discovered about these stocks read the InvestorsObserver's PriceWatch Alerts at http://www.investorsobserver.com/pr/6620134 (Note: You may have to copy this link into your browser then press the [ENTER] key.)

Today's PriceWatch Alerts cover the following stocks: Priceline com (Nasdaq: PCLN), Mylan Laboratories (Nasdaq: MYL), Ctrip Com (Nasdaq: CTRP), ResMed (NYSE: RMD), and AOL (NYSE: AOL).

InvestorsObserver's PriceWatch Alerts contain concise, detailed strategies for each stock we cover, including position protection tactics designed to defend investors from potential market shifts. While many other market reports only provide stock news and opinion, we offer strategies that can bulwark investments against uncertainty and increase chances of making a profit, even if a stock goes down.

"We go above and beyond typical market coverage," said Bobby Raines, Analyst at InvestorsObserver. "Trading experts and beginning investors alike can find value in our PriceWatch Alerts. We provide actionable strategies that protect investments with basic hedging tactics, along with a concise explanation of our techniques."

For essential information on stocks poised to move go to:

http://www.investorsobserver.com/pr/6620134 for InvestorsObserver's PriceWatch Alerts.

InvestorsObserver.com is an online newsletter which focuses on the U.S. equities and options markets. Our analytical tools, screening techniques, rigorous research methods and committed staff provide solid information to help subscribers make the best possible investment decisions. For more information go to www.investorsobserver.com.

All stocks and options shown are examples only-- not recommendations to buy or sell. Our picks do not represent a positive or negative outlook on any security.  Potential returns do not take into account your trade size, brokerage commissions or taxes--expenses that will affect actual investment returns. Stocks and options involve risk, thus they are not suitable for all investors. Prior to buying or selling options, a person should request a copy of Characteristics and Risks of Standardized Options available at http://www.cboe.com/Resources/Intro.aspx. Privacy policy available upon request.

SOURCE InvestorsObserver


Quelle: PR Newswire  

Zeit  Kurs  Stück  
08:15:52 23,434 €  499  
08:15:07 23,333 €  301

....nächste Brief Abfahrt mit 23,373 / Angaben Tradegate RT  

34th Annual Global Healthcare Conference15:05 12.06.13


PR Newswire

PITTSBURGH, June 12, 2013

PITTSBURGH, June 12, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that Executive Chairman Robert Coury and Chief Financial Officer John Sheehan will speak at the Goldman Sachs 34th Annual Global Healthcare Conference on Wednesday, June 12, 2013 at 10 a.m. PDT, 1 p.m. EDT, at the Terranea Resort, Rancho Palos Verdes, California. The conference will be webcast live and can be accessed on Mylan's Investor Relations Web site at http://investor.mylan.com/. The webcast also can be accessed at the following URL:

http://cc.talkpoint.com/gold006/061113a_gm/?entity=28_WOF84U4

An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.


Quelle: PR Newswire  

31,34 $ +1,69% +0,52 $ , 22:00 MEZ , GrB  

US-amerikanischen Pharmaunternehmen. Kernkompetenz der Gesellschaft ist die Entwicklung, Herstellung und Vermarktung von Generika (Nachahmer-Medikamente, deren Patentschutz abgelaufen ist) und eigenen Marken-Pharmazeutika. Zudem werden aktive pharmazeutische Inhaltsstoffe (API) für die Pharmaindustrie angeboten. Zu den im Produktportfolio befindlichen Generika gehören solche gegen Herz-Kreislauf-Beschwerden (z.B. Clonidine Transdermal System), gegen Diabetes (z.B. Glipizide und Metformin Hydrochloride Tabletten) oder gegen vermindernden Harndrang (z.B. Spironolactone). Hier umfasst das Sortiment des Konzerns derzeit über 1100 verschiedene Produkte. Mit seinen Tochtergesellschaften Merck Generics, Mylan Pharmaceuticals und UDL Laboratories werden in fast allen Therapiegebieten kostengünstige Standardtherapien durch qualitativ hochwertige generische Arzneimittel auf den Markt gebracht. Eine besondere Kompetenz hat das Unternehmen zudem bei der Verabreichung von Wirkstoffen über die Haut mittels spezieller Pflaster. Im Bereich der Markenprodukte bietet Mylan vor allem spezielle Aerosole und Injektoren an.  

with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign13:05 18.06.13


PR Newswire

BASKING RIDGE, N.J., June 18, 2013

BASKING RIDGE, N.J., June 18, 2013 /PRNewswire/ -- Pro football player and 2012 most valuable player (MVP) Adrian Peterson and professional family expert Jo Frost have potentially life-threatening (severe) allergies and are partnering with Mylan Specialty L.P., the fully integrated specialty pharmaceutical business of Mylan Inc. (Nasdaq: MYL), to raise awareness of this significant health problem. In recognition of the 25th anniversary of the U.S. Food and Drug Administration (FDA) approval of EpiPen® (epinephrine) Auto-Injector, Mylan Specialty is launching a multi-channel campaign to further improve preparedness for life-threatening allergic reactions (anaphylaxis) and to encourage people to Show Us Your EpiPens™ at www.25YearsofEpiPen.com.

"Life-threatening allergic reactions are unpredictable and symptoms can progress rapidly from mild to severe, which is why immediate access to epinephrine, the only first-line treatment for anaphylaxis is critical," said Phil Lieberman, M.D., Clinical Professor of Medicine and Pediatrics, University of Tennessee College of Medicine, Memphis, Tenn. "I've seen many patients underestimate their risk of anaphylaxis and overestimate their preparedness. People with severe allergies should have an anaphylaxis action plan in place, which includes avoiding known allergens, recognizing symptoms, having access to two epinephrine auto-injectors at all times and seeking immediate emergency medical care should anaphylaxis occur."

This effort, spearheaded by Adrian and Jo, will demonstrate how living with severe allergies is part of their life experience, but doesn't define who they are or hold them back from success. They are asking others to join in the 25th anniversary celebration and help spread the word about the importance of being better prepared for anaphylaxis by uploading a photo to show how you take your EpiPen Auto-Injectors with you everywhere you go from home to school, to the office and even on trips and vacations. Additionally, Adrian and Jo are dispelling misperceptions about anaphylaxis throughout the campaign, including a series of videos featured on the website.

For every photo submission, Mylan Specialty will donate $25 to leading allergy non-profit groups up to a total of $25,000. In addition, people who upload a photo can choose to receive an exclusive copy of the EpiPen® Show and Tell magazine, featuring original photos, personal tips and more from Adrian and Jo (participation requires following certain guidelines, including having a valid prescription). Uploaded, approved photos will be added to an online mosaic displaying where people of all ages with severe allergies have proudly carried their EpiPen Auto-Injectors across the country and beyond.

"I've always been serious about my football career, but as of last year, I learned that I have severe allergies to shellfish, which I also now take very seriously," said Adrian Peterson, running back and 2012 pro football MVP. "I have an anaphylaxis action plan that includes avoiding my allergic triggers and carrying two EpiPen Auto-Injectors with me everywhere I go. To help spread the word about what it takes to be better prepared for anaphylaxis, I'm asking you to Show Us Your EpiPens at www.25YearsofEpiPen.com."

Unlike Adrian who had his first allergic reaction as an adult, Jo experienced anaphylaxis as a kid and has dealt with it ever since. Jo manages multiple severe allergies, including peanuts, tree nuts and shellfish. Adrian and Jo both have anaphylaxis action plans in place, which includes avoiding their allergens and carrying two EpiPen Auto-Injectors at all times, which is why they've joined forces on this campaign to underscore how important it is to be better prepared for anaphylaxis.

"For 25 years, EpiPen Auto-Injector has been part of the anaphylaxis action plans and life experience of the millions of people at risk for anaphylaxis," said Heather Bresch, CEO of Mylan. "Our anniversary celebration is the perfect opportunity for us to reflect on the progress made to date and renew our commitment to support the community impacted by severe allergies, as we continue our educational efforts and support into the future."

In recognition of the millions of people who have made EpiPen Auto-Injector the No. 1 prescribed treatment for 25 years, Mylan Specialty is expanding its long-standing support of the allergy community through added national and local efforts, such as offering a 25th anniversary $0 co-pay card, sponsoring a series of allergy awareness baseball games and food allergy walks across the country and continuing the EpiPen4Schools™ program.

Despite the increasing prevalence of food allergies, the most common cause of anaphylaxis, many people who are at risk for anaphylaxis are not ready to appropriately respond when it happens. Avoidance of allergic triggers is the critical first step to prevent a serious allergic reaction, but accidental exposure may still happen, so people need to be prepared to respond if anaphylaxis occurs.

For more information on anaphylaxis, severe allergies and EpiPen Auto-Injector, visit epipen.mediaroom.com.

Indications

EpiPen® (epinephrine) 0.3 mg and EpiPen Jr® (epinephrine) 0.15 mg Auto-Injectors are for the emergency treatment of life-threatening allergic reactions (anaphylaxis) caused by allergens, exercise, or unknown triggers; and for people who are at increased risk for these reactions. EpiPen and EpiPen Jr are intended for immediate self administration as emergency supportive therapy only. Seek immediate emergency medical treatment after use.

Important Safety Information

EpiPen Auto-Injectors contain a single dose of epinephrine, which you inject into your outer thigh. DO NOT INJECT INTO YOUR VEIN, BUTTOCK, FINGERS, TOES, HANDS OR FEET. In case of accidental injection, please seek immediate medical treatment. Epinephrine should be used with caution if you have heart disease or are taking certain medicines that can cause heart-related (cardiac) symptoms.

Tell your doctor if you have certain medical conditions such as asthma, depression, thyroid disease, Parkinson's disease, diabetes, high blood pressure and heart disease, have any other medical conditions, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Be sure to also tell your doctor all the medicines you take, especially medicines for asthma. If you have certain medical conditions, or take certain medicines, your condition may get worse or you may have longer lasting side effects when you take the EpiPen or EpiPen Jr Auto-Injector.

The most common side effects may include increase in heart rate, stronger or irregular heartbeat, sweating, nausea and vomiting, difficulty breathing, paleness, dizziness, weakness or shakiness, headache, apprehension, nervousness or anxiety. These side effects usually go away quickly, especially if you rest.

Talk to your healthcare professional to see if EpiPen or EpiPen Jr Auto-Injector is right for you.

Please click here or visit www.EpiPen.com for the EpiPen Auto-Injector prescribing information.



Please click here or visit www.EpiPen.com for the EpiPen Auto-Injector patient information.

You are encouraged to report negative side effects of prescription drugs to the FDA.



Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

About Anaphylaxis

Anaphylaxis is a life-threatening allergic reaction that has many possible triggers, occurs quickly, without warning, and must be treated immediately with epinephrine. Symptoms may include hives or redness of the skin, tightness in the throat, nausea, dizziness, breathing problems, a decrease in blood pressure and/or fainting. Anaphylaxis can be caused by triggers such as food, stinging and biting insects, medicines, latex or even exercise. Epinephrine is the only first-line treatment for anaphylaxis. According to the food allergy guidelines developed by the National Institute of Allergy and Infectious Diseases, if experiencing anaphylaxis, a person should use an epinephrine auto-injector and seek immediate emergency medical attention. Epinephrine is a naturally-occurring hormone, also known as adrenaline, and it should be available at all times to patients at risk. Delays in epinephrine administration have been associated with negative health consequences, even possibly death.

About the "$0 Co-Pay Offer" Card

Mylan Specialty is excited to offer the 25th anniversary "$0 Co-Pay Offer" card to provide additional support to patients. The offer is available to both cash-paying and commercially insured patients, including those with a high deductible. Certain restrictions apply. The "$0 Co-Pay Offer" (with maximum benefit up to $100 per each EpiPen 2-Pak®) is valid for up to three EpiPen 2-Pak cartons or EpiPen Jr 2-Pak® cartons per prescription. Eligible patients can use the offer an unlimited number of times until the expiration date, December 31, 2013. The co-pay card is available through physicians across the country. Patients can contact Mylan Customer Service at 1-800-796-9526 with any questions, and can obtain additional information about the co-pay card at www.EpiPen.com. In addition to this offer, EpiPen Auto-Injector continues to have more than 97% Tier 2 Preferred Commercial Coverage.

About the EpiPen4Schools™ Program

Through the EpiPen4Schools program, Mylan Specialty will offer four free EpiPen or EpiPen Jr Auto-Injectors, upon qualification, which includes having a valid prescription, to public and private kindergarten, elementary, middle and high schools in the U.S. The products will be available in the form of two EpiPen 2-Pak cartons, two EpiPen Jr 2-Pak cartons, or one 2-Pak of each kind. To participate, a school nurse or other authorized school representative must visit www.EpiPen4Schools.com to download the order and certification form, then fax or email the form with a valid prescription to 1-973-718-4328 or info@bioridgepharma.com. Alternately, school representatives can call 1-973-845-7600 to speak with a live representative.

In addition to the EpiPen4Schools program, Mylan Specialty offers a discount program through which schools can purchase, upon qualification, EpiPen 2-Pak cartons and EpiPen Jr 2-Pak cartons at a discounted price. There is no requirement for a school to purchase additional EpiPen Auto-Injectors or any other Mylan Specialty products.

About EpiPen Auto-Injector

EpiPen and EpiPen Jr Auto-Injectors are used for the emergency treatment of life-threatening allergic reactions. Each EpiPen 2-Pak and EpiPen Jr 2-Pak contains two single auto-injectors, instructions for use and a training device, with no drug product or needle, to help patients become familiar with the administration technique. EpiPen Auto-Injector should be administered immediately at the first sign of an anaphylactic reaction. EpiPen Auto-Injector is not a substitute for emergency medical treatment. Patients should seek emergency medical attention immediately following administration. EpiPen Auto-Injector has been the No. 1 prescribed epinephrine auto-injector for 25 years and has three-step easy-to-follow instructions for use. For more information about EpiPen Auto-Injector, please visit www.EpiPen.com.

About Mylan Specialty

Mylan Specialty, a subsidiary of Mylan Inc. (NASDAQ: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, life-threatening allergic reactions and psychiatric disorders. For more information, please visit www.mylanspecialty.com.

About Mylan

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

EpiPen®, EpiPen Jr®, EpiPen 2-Pak® and EpiPen Jr 2-Pak® are registered trademarks of Mylan Inc. licensed exclusively to its wholly-owned subsidiary, Mylan Specialty L.P.

Show Us Your EpiPens™ is a trademark of Mylan Specialty L.P.

EpiPen4SchoolsTM is a trademark of Mylan Inc.

© 2013 Mylan Specialty L.P. All rights reserved.

EPI-2013-0089/EPI564501-01

SOURCE Mylan Inc.


Quelle: PR Newswire  

12:36 19.06.13

DARMSTADT (dpa-AFX) - Der Pharma-Konzern Merck KGaA (Merck KGaA Aktie) wehrt sich möglicherweise gegen ein millionenschweres EU-Bußgeld wegen Wettbewerbsverzerrung. Man werde in der zugelassenen Frist von zwei Monaten und zehn Tagen prüfen, ob man Rechtsmittel beim Europäischen Gerichtshof einlege, erklärte ein Unternehmenssprecher am Mittwoch in Darmstadt.

Die Europäische Kommission hat den dänischen Hersteller des Anti-Depressivums "Citalopram", Lundbeck, und vier Hersteller von Nachahmermedikamenten zu hohen Geldbußen verurteilt, weil sie 2002 auf Betreiben der Dänen den Markteintritt der billigeren Generika verzögert haben sollen. Lundbeck soll 93,8 Millionen Euro zahlen und Merck 21,4 Millionen Euro. Der Dax (DAX)-Konzern bestätigt die Existenz einer Vereinbarung. Sie habe aber damals nicht gegen geltendes Wettbewerbsrecht verstoßen.

Merck hat das Generika-Geschäft im Mai 2007 an das US-Unternehmen Mylan (Mylan Aktie) verkauft, haftet aber noch für ältere Rechtsrisiken. Nach Angaben des Sprechers sind Rückstellungen gebildet worden, so dass die Buße keinen Einfluss auf das Finanzergebnis haben würde./ceb/mt/DP/mne

Quelle: dpa-AFX